arrow
M

Mohammed Abu-Rumaileh

University System of Ohio
H指数:4
被引数:86

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Allopurinol Use Is Associated with Decreased Incidence of Hepatic Decompensation and Overall Mortality among Individuals with Cirrhosis: A Propensity-Matched Cohort Study

别嘌醇的使用与肝硬化患者肝功能失代偿发生率及总死亡率的降低相关:一项倾向性匹配队列研究

2025-12-010
OA
Comparative Risk of Infection-Related Hospitalization With Infliximab, Vedolizumab, and Ustekinumab in Elderly Inflammatory Bowel Disease: A Propensity-Score-Matched

感染相关住院的老年炎症性肠病患者中英夫利昔单抗、维多利珠单抗和乌司奴单抗的相对风险比较:一项倾向性评分匹配研究

2025-10-010
PRE
Tofacitinib vs Vedolizumab: A 36-Month Journey in Ulcerative Proctitis Management With Insights on Efficacy and Safety: Propensity-Matched Cohort Analysis Using TriNetX Database

托法替尼 vs. 韦多利珠单抗:溃疡性直肠炎管理中的36个月旅程——关于疗效和安全性的见解:基于TriNetX数据库的倾向性匹配队列分析

2025-10-010
PRE
Efficacy and Safety of 14-Day Vonoprazan-Based Quadruple Therapy vs PPI-Based Regimens for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis

14天沃诺拉赞为基础的四联疗法与PPI为基础的方案治疗幽门螺杆菌根除的疗效与安全性:一项系统评价和Meta分析

2025-10-010
PRE
Efficacy of Potassium Channel Acid Blockers for Non-Erosive Reflux Disease: A Systematic Review and Meta-Analysis

钾通道酸阻滞剂对非糜烂性反流病的疗效:一项系统评价和荟萃分析

2025-10-010
PRE
COMPARATIVE EFFECTIVENESS OF ORAL JANUS KINASE INHIBITORS VERSUS VEDOLIZUMAB IN ULCERATIVE COLITIS AFTER ANTI-TNF THERAPY FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS

抗肿瘤坏死因子治疗失败后,口服JAK抑制剂与 Vedolizumab 在溃疡性结肠炎中的比较有效性:一项系统评价和荟萃分析

2025-02-280
PRE